ABVC BioPharma, Inc. (ECOC) Gross margin 2019–2025
ABVC BioPharma, Inc. (ECOC) gross margin by fiscal year — reported gross profit divided by reported revenue.
171.9%FY2025 · since FY2019: -25.4% → 171.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 171.9% | +201.3 pp |
| FY2024 | -29.4% | -477.7 pp |
| FY2023 | 448.3% | +412.2 pp |
| FY2022 | 36.2% | -94.3 pp |
| FY2021 | 130.5% | -10.6 pp |
| FY2020 | 141.1% | +166.5 pp |
| FY2019 | -25.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ECOC financial trends
ECOC RevenueECOC Net incomeECOC Net marginECOC Gross profitECOC Operating incomeECOC Operating marginECOC Operating cash flowECOC Free cash flowECOC Capital expendituresECOC Return on equityECOC Stock buybacksECOC Dividends paidECOC Total assetsECOC Total liabilitiesECOC Shareholders’ equityECOC overview →